Clinical decisions made by health professionals to recommend either drug or probiotic interventions for irritable bowel syndrome (IBS) should be supported by proper knowledge of the efficacy rates of both types of interventions. In this article, we performed a systematic review and meta-analysis to examine the efficacy of both probiotic- and drug interventions in IBS. Medline was searched between January 2015 – January 2021. Randomised controlled trials (RCT) recruiting participants > 18 years old with IBS and examining the effect of probiotics or drugs were eligible for inclusion. The data of the primary outcome, i.e. the persistence of IBS symptoms (dichotomous symptom data), were pooled to obtain a relative risk (RR), with a 95% confidence interval (CI). Secondary outcomes, abdominal pain- and bloating scores (continuous data), were pooled using a standardised mean difference with a 95% CI. The search identified 269 citations of which 32 RCTs were eligible. Our meta-analysis indicated that both probiotic and drug interventions are able to improve the persistence of IBS symptoms (RR 0.60 [0.51; 0.92] versus 0.87 [0.81; 0.92], respectively) and abdominal pain scores (standardised mean difference (SMD) -0.35 [-0.56; -0.14] versus -0.10 [-0.20; 0.00], respectively). However, determining the overall efficacy of both intervention types is inherently complex and such results should be interpreted with care, due to the large diversity of probiotic- and drug types and doses, which is also complicated by variety in IBS subtypes. Hence, as a first step, more large scale randomised double blind placebo-controlled trials focussing on a specific IBS subtype targeted with specific probiotic strains or specific pharmaceutical modalities should be executed, enabling a more proper comparison between trials.
Alesa, D.I., Alshamrani, H.M., Alzahrani, Y.A., Alamssi, D.N., Alzahrani, N.S. and Almohammadi, M.E., 2019. The role of gut microbiome in the pathogenesis of psoriasis and the therapeutic effects of probiotics. Journal of Family Medicine and Primary Care 8: 3496.
'The role of gut microbiome in the pathogenesis of psoriasis and the therapeutic effects of probiotics ' () 8 Journal of Family Medicine and Primary Care : 3496.
Andresen, V., Gschossmann, J. and Layer, P., 2020. Heat-inactivated Bifidobacterium bifidum MIMBb75 (SYN-HI-001) in the treatment of irritable bowel syndrome: a multicentre, randomised, doubleblind, placebo-controlled clinical trial. The Lancet Gastroenterology and Hepatology 5: 658-666.
'Heat-inactivated Bifidobacterium bifidum MIMBb75 (SYN-HI-001) in the treatment of irritable bowel syndrome: a multicentre, randomised, doubleblind, placebo-controlled clinical trial ' () 5 The Lancet Gastroenterology and Hepatology : 658 -666.
Ansari, F., Pourjafar, H., Tabrizi, A. and Homayouni, A., 2020. The effects of probiotics and prebiotics on mental disorders: a review on depression, anxiety, Alzheimer, and autism spectrum disorders. Current Pharmaceutical Biotechnology 21: 555-565.
'The effects of probiotics and prebiotics on mental disorders: a review on depression, anxiety, Alzheimer, and autism spectrum disorders ' () 21 Current Pharmaceutical Biotechnology : 555 -565.
Barbara, G., Cremon, C., Annese, V., Basilisco, G., Bazzoli, F., Bellini, M., Benedetti, A., Benini, L., Bossa, F. and Buldrini, P., 2016. Randomised controlled trial of mesalazine in IBS. Gut 65: 82-90.
'Randomised controlled trial of mesalazine in IBS ' () 65 GutGut : 82 -90.
Barberio, B., Houghton, L.A., Yiannakou, Y., Savarino, E.V., Black, C. J. and Ford, A.C., 2021. Symptom stability in Rome IV vs Rome III irritable bowel syndrome. Official Journal of the American College of Gastroenterology 116: 362-371. https://doi.org/10.14309/ajg.0000000000000946
Blaabjerg, S., Artzi, D.M. and Aabenhus, R., 2017. Probiotics for the prevention of antibiotic-associated diarrhea in outpatients – a systematic review and meta-analysis. Antibiotics 6: 21.
'Probiotics for the prevention of antibiotic-associated diarrhea in outpatients – a systematic review and meta-analysis ' () 6 Antibiotics : 21.
Bonfrate, L., Di Palo, D.M., Celano, G., Albert, A., Vitellio, P., De Angelis, M., Gobbetti, M. and Portincasa, P., 2020. Effects of Bifidobacterium longum BB536 and Lactobacillus rhamnosus HN001 in IBS patients. European Journal of Clinical Investigation 50: e13201.
'Effects of Bifidobacterium longum BB536 and Lactobacillus rhamnosus HN001 in IBS patients ' () 50 European Journal of Clinical Investigation : e13201.
Brenner, D.M., Fogel, R., Dorn, S.D., Krause, R., Eng, P., Kirshoff, R., Nguyen, A., Crozier, R.A., Magnus, L. and Griffin, P.H., 2018. Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials. American Journal of Gastroenterology 113: 735-745.
'Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials ' () 113 American Journal of Gastroenterology : 735 -745.
Brenner, D.M., Sayuk, G.S., Gutman, C.R., Jo, E., Elmes, S.J., Liu, L.W. and Cash, B.D., 2019. Efficacy and safety of eluxadoline in patients with irritable bowel syndrome with diarrhea who report inadequate symptom control with loperamide: RELIEF phase 4 study. American Journal of Gastroenterology 114: 1502.
'Efficacy and safety of eluxadoline in patients with irritable bowel syndrome with diarrhea who report inadequate symptom control with loperamide: RELIEF phase 4 study ' () 114 American Journal of Gastroenterology : 1502.
Camilleri, M. and Ford, A.C., 2017. Irritable bowel syndrome: pathophysiology and current therapeutic approaches. In: Greenwood-Van Meerveld, B. (ed.), Gastrointestinal pharmacology. Springer International Publishing, Cham, Switzerland, pp. 75-113. https://doi.org/10.1007/164_2016_102
Canavan, C., West, J. and Card, T., 2014. The economic impact of the irritable bowel syndrome. Alimentary Pharmacology and Therapeutics 40: 1023-1034.
'The economic impact of the irritable bowel syndrome ' () 40 Alimentary Pharmacology and Therapeutics : 1023 -1034.
Chey, W.D., Lembo, A.J. and Rosenbaum, D.P., 2017. Tenapanor treatment of patients with constipation-predominant irritable bowel syndrome: a phase 2, randomized, placebo-controlled efficacy and safety trial. American Journal of Gastroenterology 112: 763.
'Tenapanor treatment of patients with constipation-predominant irritable bowel syndrome: a phase 2, randomized, placebo-controlled efficacy and safety trial ' () 112 American Journal of Gastroenterology : 763.
Chey, W.D., Lembo, A.J. and Rosenbaum, D.P., 2020. Efficacy of tenapanor in treating patients with irritable bowel syndrome with constipation: a 12-week, placebo-controlled phase 3 trial (T3MPO-1). American Journal of Gastroenterology 115: 281.
'Efficacy of tenapanor in treating patients with irritable bowel syndrome with constipation: a 12-week, placebo-controlled phase 3 trial (T3MPO-1) ' () 115 American Journal of Gastroenterology : 281.
De Chambrun, G.P., Neut, C., Chau, A., Cazaubiel, M., Pelerin, F., Justen, P. and Desreumaux, P., 2015. A randomized clinical trial of Saccharomyces cerevisiae versus placebo in the irritable bowel syndrome. Digestive and Liver Disease 47: 119-124.
'A randomized clinical trial of Saccharomyces cerevisiae versus placebo in the irritable bowel syndrome ' () 47 Digestive and Liver Disease : 119 -124.
Egger, M., Smith, G.D., Schneider, M. and Minder, C., 1997. Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634.
'Bias in meta-analysis detected by a simple, graphical test ' () 315 BMJ : 629 -634.
Faghihi, A.H., Agah, S., Masoudi, M., Ghafoori, S. and Eshraghi, A., 2015. Efficacy of probiotic Escherichia coli Nissle 1917 in patients with irritable bowel syndrome: a double blind placebo-controlled randomized trial. Acta Medica Indonesiana 47: 201-208.
'Efficacy of probiotic Escherichia coli Nissle 1917 in patients with irritable bowel syndrome: a double blind placebo-controlled randomized trial ' () 47 Acta Medica Indonesiana : 201 -208.
Ford, A.C., Harris, L.A., Lacy, B.E., Quigley, E.M. and Moayyedi, P., 2018. Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. Alimentary Pharmacology and Therapeutics 48: 1044-1060.
'Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome ' () 48 Alimentary Pharmacology and Therapeutics : 1044 -1060.
Fukudo, S., Endo, Y., Hongo, M., Nakajima, A., Abe, T., Kobayashi, H., Nakata, T., Nakajima, T., Sameshima, K. and Kaku, K., 2018a. Safety and efficacy of the sodium-glucose cotransporter 1 inhibitor mizagliflozin for functional constipation: a randomised, placebocontrolled, double-blind phase 2 trial. The Lancet Gastroenterology and Hepatology 3: 603-613.
'Safety and efficacy of the sodium-glucose cotransporter 1 inhibitor mizagliflozin for functional constipation: a randomised, placebocontrolled, double-blind phase 2 trial ' () 3 The Lancet Gastroenterology and Hepatology : 603 -613.
Fukudo, S., Kinoshita, Y., Okumura, T., Ida, M., Akiho, H., Nakashima, Y., Nishida, A. and Haruma, K., 2016. Ramosetron reduces symptoms of irritable bowel syndrome with diarrhea and improves quality of life in women. Gastroenterology 150: 358-366. e358.
'Ramosetron reduces symptoms of irritable bowel syndrome with diarrhea and improves quality of life in women ' () 150 Gastroenterology .
Fukudo, S., Matsueda, K., Haruma, K., Ida, M., Hayase, H., Akiho, H., Nakashima, Y. and Hongo, M., 2017. Optimal dose of ramosetron in female patients with irritable bowel syndrome with diarrhea: a randomized, placebo-controlled phase II study. Neurogastroenterology and Motility 29: e13023.
'Optimal dose of ramosetron in female patients with irritable bowel syndrome with diarrhea: a randomized, placebo-controlled phase II study ' () 29 Neurogastroenterology and Motility : e13023.
Fukudo, S., Miwa, H., Nakajima, A., Haruma, K., Kosako, M., Nakagawa, A., Akiho, H., Yamaguchi, Y., Johnston, J.M. and Currie, M., 2018b. A randomized controlled and long-term linaclotide study of irritable bowel syndrome with constipation patients in Japan. Neurogastroenterology and Motility 30: e13444.
'A randomized controlled and long-term linaclotide study of irritable bowel syndrome with constipation patients in Japan ' () 30 Neurogastroenterology and Motility : e13444.
Fukudo, S., Nakajima, A., Fujiyama, Y., Kosako, M., Nakagawa, A., Akiho, H., Nakashima, Y., Johnston, J. and Miwa, H., 2018c. Determining an optimal dose of linaclotide for use in Japanese patients with irritable bowel syndrome with constipation: a phase II randomized, double-blind, placebo-controlled study. Neurogastroenterology and Motility 30: e13275.
'Determining an optimal dose of linaclotide for use in Japanese patients with irritable bowel syndrome with constipation: a phase II randomized, double-blind, placebo-controlled study ' () 30 Neurogastroenterology and Motility : e13275.
Higgins, J.P., Thompson and S.G., 2002. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 21:1539-1558.
'Quantifying heterogeneity in a meta-analysis ' () 21 Statistics in Medicine : 1539 -1558.
Hill, C., Guarner, F., Reid, G., Gibson, G.R., Merenstein, D.J., Pot, B., Morelli, L., Canani, R.B., Flint, H.J., Salminen, S., Calder, P.C. and Sanders, M.E., 2014. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nature Reviews Gastroenterology & Hepatology 11: 506-514. https://doi.org/10.1038/nrgastro.2014.66
Hod, K., Sperber, A., Ron, Y., Boaz, M., Dickman, R., Berliner, S., Halpern, Z., Maharshak, N. and Dekel, R., 2017. A double-blind, placebo-controlled study to assess the effect of a probiotic mixture on symptoms and inflammatory markers in women with diarrhea-predominant IBS. Neurogastroenterology and Motility 29: e13037.
'A double-blind, placebo-controlled study to assess the effect of a probiotic mixture on symptoms and inflammatory markers in women with diarrhea-predominant IBS ' () 29 Neurogastroenterology and Motility : e13037.
Ishaque, S.M., Khosruzzaman, S., Ahmed, D.S. and Sah, M.P., 2018. A randomized placebo-controlled clinical trial of a multi-strain probiotic formulation (Bio-Kult®) in the management of diarrhea-predominant irritable bowel syndrome. BMC Gastroenterology 18: 1-12.
'A randomized placebo-controlled clinical trial of a multi-strain probiotic formulation (Bio-Kult®) in the management of diarrhea-predominant irritable bowel syndrome ' () 18 BMC Gastroenterology : 1 -12.
Jahani-Sherafat, S., Alebouyeh, M., Moghim, S., Amoli, H.A. and Ghasemian-Safaei, H., 2018. Role of gut microbiota in the pathogenesis of colorectal cancer; a review article. Gastroenterology and hepatology from bed to bench 11: 101.
'Role of gut microbiota in the pathogenesis of colorectal cancer; a review article ' () 11 Gastroenterology and hepatology from bed to bench : 101.
Kanbay, M., Onal, E.M., Afsar, B., Dagel, T., Yerlikaya, A., Covic, A. and Vaziri, N.D., 2018. The crosstalk of gut microbiota and chronic kidney disease: role of inflammation, proteinuria, hypertension, and diabetes mellitus. International Urology and Nephrology 50: 1453-1466.
'The crosstalk of gut microbiota and chronic kidney disease: role of inflammation, proteinuria, hypertension, and diabetes mellitus ' () 50 International Urology and Nephrology : 1453 -1466.
Lam, C., Tan, W., Leighton, M., Hastings, M., Lingaya, M., Falcone, Y., Zhou, X., Xu, L., Whorwell, P. and Walls, A.F., 2016. A mechanistic multicentre, parallel group, randomised placebo-controlled trial of mesalazine for the treatment of IBS with diarrhoea (IBS-D). Gut 65: 91-99.
'A mechanistic multicentre, parallel group, randomised placebo-controlled trial of mesalazine for the treatment of IBS with diarrhoea (IBS-D) ' () 65 Gut : 91 -99.
Larsen, O.F.A., Van den Nieuwboer, M., Koks, M., Flach, J. and Claassen, E., 2017. Probiotics for healthy ageing: Innovation barriers and opportunities for bowel habit improvement in nursing homes. Agro Food Industry Hi Tech 28: 12-15.
'Probiotics for healthy ageing: Innovation barriers and opportunities for bowel habit improvement in nursing homes ' () 28 Agro Food Industry Hi Tech : 12 -15.
Lembo, A., Pimentel, M., Rao, S.S., Schoenfeld, P., Cash, B., Weinstock, L.B., Paterson, C., Bortey, E. and Forbes, W.P., 2016a. Repeat treatment with rifaximin is safe and effective in patients with diarrhea-predominant irritable bowel syndrome. Gastroenterology 151: 1113-1121.
'Repeat treatment with rifaximin is safe and effective in patients with diarrhea-predominant irritable bowel syndrome ' () 151 Gastroenterology : 1113 -1121.
Lembo, A.J., Lacy, B.E., Zuckerman, M.J., Schey, R., Dove, L.S., Andrae, D.A., Davenport, J.M., McIntyre, G., Lopez, R. and Turner, L., 2016b. Eluxadoline for irritable bowel syndrome with diarrhea. New England Journal of Medicine 374: 242-253.
'Eluxadoline for irritable bowel syndrome with diarrhea ' () 374 New England Journal of Medicine : 242 -253.
Lyra, A., Hillilä, M., Huttunen, T., Männikkö, S., Taalikka, M., Tennilä, J., Tarpila, A., Lahtinen, S., Ouwehand, A.C. and Veijola, L., 2016. Irritable bowel syndrome symptom severity improves equally with probiotic and placebo. World Journal of Gastroenterology 22: 10631.
'Irritable bowel syndrome symptom severity improves equally with probiotic and placebo ' () 22 World Journal of Gastroenterology : 10631.
Mai, T.T., Thu, P.T., Hang, H.T., Trang, T.T.T., Yui, S., Shigehisa, A., Tien, V.T., Dung, T.V., Nga, P.B. and Hung, N.T., 2021. Efficacy of probiotics on digestive disorders and acute respiratory infections: a controlled clinical trial in young Vietnamese children. European Journal of Clinical Nutrition 75: 513-520.
'Efficacy of probiotics on digestive disorders and acute respiratory infections: a controlled clinical trial in young Vietnamese children ' () 75 European Journal of Clinical Nutrition : 513 -520.
Martoni, C.J., Srivastava, S. and Leyer, G.J., 2020. Lactobacillus acidophilus DDS-1 and Bifidobacterium lactis UABla-12 improve abdominal pain severity and symptomology in irritable bowel syndrome: randomized controlled trial. Nutrients 12: 363.
'Lactobacillus acidophilus DDS-1 and Bifidobacterium lactis UABla-12 improve abdominal pain severity and symptomology in irritable bowel syndrome: randomized controlled trial ' () 12 Nutrients : 363.
Mezzasalma, V., Manfrini, E., Ferri, E., Sandionigi, A., La Ferla, B., Schiano, I., Michelotti, A., Nobile, V., Labra, M. and Di Gennaro, P., 2016. A randomized, double-blind, placebo-controlled trial: the efficacy of multispecies probiotic supplementation in alleviating symptoms of irritable bowel syndrome associated with constipation. BioMed Research International 2016: 4740907.
'A randomized, double-blind, placebo-controlled trial: the efficacy of multispecies probiotic supplementation in alleviating symptoms of irritable bowel syndrome associated with constipation ' () 2016 BioMed Research International : 4740907.
Mukhtar, K., Nawaz. H. and Abid, S., 2019. Functional gastrointestinal disorders and gut-brain axis: what does the future hold? World Journal of Gastroenterology 25: 552-566. https://doi.org/10.3748/wjg.v25.i5.552
Nee, J., Salley, K., Ludwig, A.G., Sommers, T., Ballou, S., Takazawa, E., Duehren, S., Singh, P., Iturrino, J. and Katon, J., 2019. Randomized clinical trial: crofelemer treatment in women with diarrhea-predominant irritable bowel syndrome. Clinical and Translational Gastroenterology 10: e00110.
'Randomized clinical trial: crofelemer treatment in women with diarrhea-predominant irritable bowel syndrome ' () 10 Clinical and Translational Gastroenterology : e00110.
Niu, H.-L. and Xiao, J.-Y., 2020. The efficacy and safety of probiotics in patients with irritable bowel syndrome: evidence based on 35 randomized controlled trials. International Journal of Surgery 75: 116-127.
'The efficacy and safety of probiotics in patients with irritable bowel syndrome: evidence based on 35 randomized controlled trials ' () 75 International Journal of Surgery : 116 -127.
Oh, J.H., Jang, Y.S., Kang, D., Chang, D.K. and Min, Y.W., 2019. Efficacy and safety of new Lactobacilli probiotics for unconstipated irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. Nutrients 11: 2887.
'Efficacy and safety of new Lactobacilli probiotics for unconstipated irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial ' () 11 Nutrients : 2887.
Oka, P., Parr, H., Barberio, B., Black, C.J., Savarino, E.V. and Ford, A.C., 2020. Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis. The Lancet Gastroenterology and Hepatology 5: 908-917.
'Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis ' () 5 The Lancet Gastroenterology and Hepatology : 908 -917.
Ouwehand, A., 2017. A review of dose-responses of probiotics in human studies. Beneficial Microbes 8: 143-151.
'A review of dose-responses of probiotics in human studies ' () 8 Beneficial Microbes : 143 -151.
Ouwehand, A.C., Invernici, M.M., Furlaneto, F.A. and Messora, M.R., 2018. Effectiveness of multi-strain versus single-strain probiotics: current status and recommendations for the future. Journal of Clinical Gastroenterology 52: S35-S40.
'Effectiveness of multi-strain versus single-strain probiotics: current status and recommendations for the future ' () 52 Journal of Clinical Gastroenterology : S35 -S40.
Preston, K., Krumian, R., Hattner, J., de Montigny, D., Stewart, M. and Gaddam, S., 2018. Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R and Lactobacillus rhamnosus CLR2 improve quality-of-life and IBS symptoms: a double-blind, randomised, placebocontrolled study. Beneficial Microbes 9: 697-706.
'Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R and Lactobacillus rhamnosus CLR2 improve quality-of-life and IBS symptoms: a double-blind, randomised, placebocontrolled study ' () 9 Beneficial Microbes : 697 -706.
R Core Team, 2020. A language and environment for statistical computing. R foundation for Statistical Computing.
Reid, G., Jass, J., Sebulsky, M.T. and McCormick, J.K., 2003. Potential uses of probiotics in clinical practice. Clinical Microbiology Reviews 16: 658-672.
'Potential uses of probiotics in clinical practice ' () 16 Clinical Microbiology Reviews : 658 -672.
Saito, Y.A., Almazar, A.E., Tilkes, K.E., Choung, R.S., Van Norstrand, M.D., Schleck, C.D., Zinsmeister, A.R. and Talley, N.J., 2019. Randomised clinical trial: pregabalin vs placebo for irritable bowel syndrome. Alimentary Pharmacology and Therapeutics 49: 389-397.
'Randomised clinical trial: pregabalin vs placebo for irritable bowel syndrome ' () 49 Alimentary Pharmacology and Therapeutics : 389 -397.
Sun, Y.-Y., Li, M., Li, Y.-Y., Li, L.-X., Zhai, W.-Z., Wang, P., Yang, X.-X., Gu, X., Song, L.-J. and Li, Z., 2018. The effect of Clostridium butyricum on symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebocontrolled trial. Scientific Reports 8: 2964.
'The effect of Clostridium butyricum on symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebocontrolled trial ' () 8 Scientific Reports : 2964.
Thijssen, A.Y., Clemens, C.H., Vankerckhoven, V., Goossens, H., Jonkers, D.M. and Masclee, A.A., 2016. Efficacy of Lactobacillus casei Shirota for patients with irritable bowel syndrome. European Journal of Gastroenterology & Hepatology 28: 8-14.
'Efficacy of Lactobacillus casei Shirota for patients with irritable bowel syndrome ' () 28 European Journal of Gastroenterology & Hepatology : 8 -14.
Van den Nieuwboer, M., Brummer, R.J., Guarner, F., Morelli, L., Cabana, M. and Claassen, E., 2015a. The administration of probiotics and synbiotics in immune compromised adults: is it safe? Beneficial Microbes 6: 3-17.
'The administration of probiotics and synbiotics in immune compromised adults: is it safe? ' () 6 Beneficial Microbes : 3 -17.
Van den Nieuwboer, M., Brummer, R.J., Guarner, F., Morelli, L., Cabana, M. and Claassen, E., 2015b. Safety of probiotics and synbiotics in children under 18 years of age. Beneficial Microbes 6: 615-630.
'Safety of probiotics and synbiotics in children under 18 years of age ' () 6 Beneficial Microbes : 615 -630.
Van den Nieuwboer, M., Claassen, E., Morelli, L., Guarner, F. and Brummer, R.J., 2014. Probiotic and synbiotic safety in infants under two years of age. Beneficial Microbes 5: 45-60.
'Probiotic and synbiotic safety in infants under two years of age ' () 5 Beneficial Microbes : 45 -60.
Van der Geest, A., Flach, J., Claassen, E., Sijlmans, A., Van de Burgwal, L. and Larsen, O., 2020. European General Practitioners perceptions on probiotics: results of a multinational survey. PharmaNutrition 11: 100178.
'European General Practitioners perceptions on probiotics: results of a multinational survey ' () 11 PharmaNutrition : 100178.
Van der Geest, A.M., Schukking, I., Brummer, R.J.M., Pieterse, H., van den Nieuwboer, M., van de Burgwal, L.H.M. and Larsen, O.F.A., 2022. Inadequate safety reporting in the publications of randomised clinical trials in irritable bowel syndrome: drug versus probiotic interventions. Beneficial Microbes, https://doi.org/BM2021.0124.
Vila, A.V., Imhann, F., Collij, V., Jankipersadsing, S.A., Gurry, T., Mujagic, Z., Kurilshikov, A., Bonder, M.J., Jiang, X. and Tigchelaar, E.F., 2018. Gut microbiota composition and functional changes in inflammatory bowel disease and irritable bowel syndrome. Science Translational Medicine 10: eaap8914.
'Gut microbiota composition and functional changes in inflammatory bowel disease and irritable bowel syndrome ' () 10 Science Translational Medicine .
Whitehead, W., Duffy, K., Sharpe, J., Nabata, T. and Bruce, M., 2017. Randomised clinical trial: exploratory phase 2 study of ONO-2952 in diarrhoea-predominant irritable bowel syndrome. Alimentary Pharmacology and Therapeutics 45: 14-26.
'Randomised clinical trial: exploratory phase 2 study of ONO-2952 in diarrhoea-predominant irritable bowel syndrome ' () 45 Alimentary Pharmacology and Therapeutics : 14 -26.
Yang, Y., Fang, J., Guo, X., Dai, N., Shen, X., Yang, Y., Sun, J., Bhandari, B.R., Reasner, D.S. and Cronin, J.A., 2018. Linaclotide in irritable bowel syndrome with constipation: a phase 3 randomized trial in China and other regions. Journal of Gastroenterology and Hepatology 33: 980-989.
'Linaclotide in irritable bowel syndrome with constipation: a phase 3 randomized trial in China and other regions ' () 33 Journal of Gastroenterology and Hepatology : 980 -989.
Yoon, J.S., Sohn, W., Lee, O.Y., Lee, S.P., Lee, K.N., Jun, D.W., Lee, H.L., Yoon, B.C., Choi, H.S., Chung, W.-S. and Seo, J.-G., 2014. Effect of multispecies probiotics on irritable bowel syndrome: A randomized, double-blind, placebo-controlled trial. Journal of Gastroenterology and Hepatology 29: 52-59. https://doi.org/10.1111/jgh.12322
Zheng, L., Lai, Y., Lu, W., Li, B., Fan, H., Yan, Z., Gong, C., Wan, X., Wu, J. and Huang, D., 2015. Pinaverium reduces symptoms of irritable bowel syndrome in a multicenter, randomized, controlled trial. Clinical Gastroenterology and Hepatology 13: 1285-1292. e1281.
'Pinaverium reduces symptoms of irritable bowel syndrome in a multicenter, randomized, controlled trial ' () 13 Clinical Gastroenterology and Hepatology .
All Time | Past 365 days | Past 30 Days | |
---|---|---|---|
Abstract Views | 0 | 0 | 0 |
Full Text Views | 314 | 288 | 62 |
PDF Views & Downloads | 399 | 378 | 51 |
Clinical decisions made by health professionals to recommend either drug or probiotic interventions for irritable bowel syndrome (IBS) should be supported by proper knowledge of the efficacy rates of both types of interventions. In this article, we performed a systematic review and meta-analysis to examine the efficacy of both probiotic- and drug interventions in IBS. Medline was searched between January 2015 – January 2021. Randomised controlled trials (RCT) recruiting participants > 18 years old with IBS and examining the effect of probiotics or drugs were eligible for inclusion. The data of the primary outcome, i.e. the persistence of IBS symptoms (dichotomous symptom data), were pooled to obtain a relative risk (RR), with a 95% confidence interval (CI). Secondary outcomes, abdominal pain- and bloating scores (continuous data), were pooled using a standardised mean difference with a 95% CI. The search identified 269 citations of which 32 RCTs were eligible. Our meta-analysis indicated that both probiotic and drug interventions are able to improve the persistence of IBS symptoms (RR 0.60 [0.51; 0.92] versus 0.87 [0.81; 0.92], respectively) and abdominal pain scores (standardised mean difference (SMD) -0.35 [-0.56; -0.14] versus -0.10 [-0.20; 0.00], respectively). However, determining the overall efficacy of both intervention types is inherently complex and such results should be interpreted with care, due to the large diversity of probiotic- and drug types and doses, which is also complicated by variety in IBS subtypes. Hence, as a first step, more large scale randomised double blind placebo-controlled trials focussing on a specific IBS subtype targeted with specific probiotic strains or specific pharmaceutical modalities should be executed, enabling a more proper comparison between trials.
All Time | Past 365 days | Past 30 Days | |
---|---|---|---|
Abstract Views | 0 | 0 | 0 |
Full Text Views | 314 | 288 | 62 |
PDF Views & Downloads | 399 | 378 | 51 |